All In Biotech

Drug Trial Radar · NCT05208047

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

482

Planned (sponsor's estimate)

Start

Apr 14, 2022

Primary completion

Sep 30, 2025

Study completion Jan 2030

Sponsor

Lead sponsor
Cogent Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).

Conditions

  • Advanced Gastrointestinal Stromal Tumors
  • Metastatic Cancer

Interventions

  • BezuclastinibDrug

    Participants will receive bezuclastinib orally until study stopping rules are met.

  • BezuclastinibDrug

    Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

  • SunitinibDrug

    Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

  • SunitinibDrug

    Participants will receive sunitinib orally until study stopping rules are met.

  • MidazolamDrug

    Participants will receive a single-dose of midazolam on Day 1 and Day 15

  • BezuclastinibDrug

    Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

  • SunitinibDrug

    Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

  • BezuclastinibDrug

    Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

  • SunitinibDrug

    Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1a - pharmacokinetics - CmaxTime frame: 16 days
  2. Part 1a - pharmacokinetics - AUCTime frame: 16 days
  3. Part 1b - pharmacokinetics - CmaxTime frame: 14 days
  4. Part 1b - pharmacokinetics - AUCTime frame: 14 days
  5. Part 1b - pharmacokinetics - TmaxTime frame: 14 days
  6. Part 2 - Progression Free Survival (PFS)Time frame: Approximately 48 months
  7. DDI Substudy - pharmacokinetics - AUCTime frame: 16 days
  8. DDI Substudy - pharmacokinetics - CmaxTime frame: 14 days

Locations

126 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Withdrawn

  • Mayo Clinic

    Scottsdale, Arizona · Recruiting

  • University of Arizona- Cancer Center

    Tucson, Arizona · Active not recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California, Los Angeles (UCLA)

    Los Angeles, California · Active not recruiting

  • University of California, San Diego (UCSD)

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Active not recruiting

  • University of Colorado Denver

    Denver, Colorado · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Withdrawn

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Active not recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Nebraska Methodist Hospital

    Omaha, Nebraska · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • The Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Toledo Medical Center

    Toledo, Ohio · Withdrawn

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Tennessee

    Knoxville, Tennessee · Withdrawn

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Active not recruiting

  • University of Wisconsin - Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • Instituto Alexander Fleming

    Buenos Aires, Argentina · Active not recruiting

  • Instituto Oncologico de Cordoba (IONC)

    Córdoba, Argentina · Active not recruiting

  • Bankstown-Lidcombe Hospital

    Bankstown, Australia · Active not recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Active not recruiting

Showing 40 of 126 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.